Wealthspring Capital
DMIIR icon

Wealthspring Capital’s Drugs Made In America Acquisition II Corp Right DMIIR Stock Holding History

Wealthspring Capital’s Portfolio DMIIR Stock Details DMIIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.7K Hold
400,440
– – 0.01% 195
2026
Q2 		$32K Sell
400,440
-2,230
-0.6% -$191 0.01% 183
2026
Q1 		$32.2K Sell
402,670
-6,280
-2% -$713 0.01% 172
2025
Q4 		$57.3K Buy
+408,950
New +$58.4K 0.01% 144

Other funds holding DMIIR

Picton Mahoney Asset Management
Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Commonwealth of Pennsylvania Public School Employees Retirement System
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $21.9B AUM 28.42% 1-Year Est. Return
Periscope Capital
Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return
Mint Tower Capital Management
Mint Tower Capital Management Amsterdam, Netherlands $589M AUM 6.02% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return

Wealthspring Capital's DMIIR Position: Q3 2026 in Review

Wealthspring Capital held its Drugs Made In America Acquisition II Corp Right (DMIIR) position steady in Q3 2026 at 400,440 shares worth $25.7K. The position accounts for 0.01% of the portfolio, ranked #195.

Wealthspring Capital first reported a position in DMIIR in Q4 2025 and has held it in 4 quarters since. The position peaked at $57.3K in Q4 2025. 9 funds tracked by Wall St. Rank hold DMIIR as of Q3 2026.

  • Wealthspring Capital held 400,440 shares of Drugs Made In America Acquisition II Corp Right worth $25.7K as of Q3 2026.
  • Wealthspring Capital left its Drugs Made In America Acquisition II Corp Right share count unchanged in Q3 2026.
  • Drugs Made In America Acquisition II Corp Right made up 0.01% of Wealthspring Capital's portfolio in Q3 2026, its #195 holding.
  • Wealthspring Capital first reported a position in Drugs Made In America Acquisition II Corp Right in Q4 2025 and has held it in 4 quarters since.
  • Wealthspring Capital's Drugs Made In America Acquisition II Corp Right position peaked at $57.3K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Right as of Q3 2026.

Based on Wealthspring Capital's 13F filing for Q3 2026, filed 4 Nov 2026.